COMP

mojoembiid

RKT just partnered with COMP and is taking off. Feel like 24 dollars is reachable. Going to place a flyer in AM

jamesd203313

HALT hungry angry lonely tired. Then reassess. NFA $COMP

Slow-Sun-2779

AI slop Been tracking Compass Pathways ($CMPS) for a while and the narrative has shifted pretty noticeably this week. For anyone not super familiar, Compass is a clinical-stage mental health biotech focused on developing COMP360, a synthetic psilocybin therapy for treatment-resistant depression (TRD) and other psychiatric indications. Back in the psychedelic stock boom of 2021, a lot of names ran hard and fast — $CMPS was no exception. Shares traded well above $40 and even near $50-plus at highs as hype around psychedelic therapeutics took off.  But like many biotechs with long regulatory paths, it didn’t translate into a straight shot higher. By 2022 and 2023, the stock had fallen off sharply — by the end of 2022 it was down into the single digits, and into 2024-2025 it even hit low-$3-range territory at times.  The reason for that multi-year sideways/low-price action was pretty simple: long clinical timelines and delayed catalysts. Psychedelic stocks in general didn’t have a staffed commercial product — and regulatory processes are slow — so prices reflected that uncertainty instead of any real revenue. Where things change is now. Today, Compass announced that the second pivotal Phase 3 trial (COMP006) for COMP360 in TRD met its primary endpoint with statistically significant improvement versus control, and a clean safety profile. The stock jumped because of this — reports showed shares up by roughly 40-45% on the day after the news.  This matters because unlike a lot of speculative names that never showed definitive controlled data, Compass is now delivering late-stage signals you can actually build a regulatory story around. Previous phase 2 data had already shown meaningful clinical responses, which is part of why the FDA gave COMP360 Breakthrough Therapy designation earlier. That essentially acknowledges the unmet need in TRD and the potential for psyilocybin to be a real treatment option instead of theoretical.  If you zoom out on the why this could be bigger long term, a few points stick out: TRD is a massive market with almost no FDA-approved options right now. Traditional antidepressants only work for some, and there’s a real gap for people who don’t respond to multiple therapies. Compare with ketamine/esketamine: J&J’s Spravato (esketamine) is approved and brings in billions annually because it’s a differentiated mechanism. Psilocybin could address a broader set of patients and has a different safety/effect profile. COMP360 doesn’t have the systemic toxicity risks associated with things like MDMA-based therapies, and MDMA isn’t even a classical psychedelic in the same sense. Analysts are still bullish on the name. There’s a consensus strong buy  Yes, it’s still clinical-stage, no revenues yet, and biotechs carry binary risk — meaning if the next regulatory review doesn’t go well or if commercial execution stumbles, the stock can go the other way. But what just changed is that the biggest binary catalyst (phase 3 proof of concept) now has a positive outcome. That’s a straightforward reason for this renewed price action after years of sluggish trading. So if you’re thinking long term, the bull case isn’t just hope — it’s that Compass has moved from “maybe” to “data in hand,” and that’s the real thing investors were waiting for before this run.

leomeng

They were buying COMP calls in high volume.

tinyregularity43

Someone really believes in COMP's turnaround story with that kind of size 13 months out - that's some serious conviction betting it hits $12+ by Jan '26

Weak-Pomegranate-435

1. **Solana (SOL)**: A high-performance Layer-1 blockchain known for ultra-fast, low-cost transactions, making it ideal for DeFi apps and NFT marketplaces. 2. **Aave (AAVE)**: A leading decentralized finance protocol that allows users to lend crypto to earn interest or borrow assets against their holdings without intermediaries. 3. **Avalanche (AVAX)**: A scalable smart contract platform capable of sub-second transaction finality and supporting custom blockchain networks (subnets). 4. **Bitcoin (BTC)**: The original decentralized digital currency that serves primarily as a secure store of value and "digital gold" independent of central banks. 5. **Jasmy (JASMY)**: An IoT (Internet of Things) platform that empowers individuals to own, manage, and monetize their personal data safely ("Data Democracy"). 6. **Polygon Ecosystem Token (POL)**: The upgraded "hyperproductive" token for the Polygon network, used to secure and scale Ethereum through zero-knowledge technology and interconnected chains. 7. **Arkham (ARKM)**: An "Intel-to-Earn" platform that deanonymizes the blockchain, rewarding users for identifying the real-world entities behind crypto wallet addresses. 8. **Render (RNDR)**: A distributed GPU rendering network that connects artists needing computing power with miners who have idle GPU capacity. 9. **Cosmos (ATOM)**: Known as the "Internet of Blockchains," it allows independent blockchains to communicate and exchange data with each other seamlessly. 10. **Onyxcoin (XCN)**: The utility and governance token for the Onyx Protocol, which facilitates decentralized cross-token liquidity, lending, and aggregated financial services. 11. **Compound (COMP)**: An algorithmic money market protocol that lets users deposit crypto to earn interest or borrow assets instantly against collateral.

AnyInjury6700

Patented synthetic psilocybin polymorph (unique crystalline structure) going through FDA clinical trials. It's currently in the second Phase 3 trial, the final stage before potential approval. On top of that you have bipartisan support in Congress, RFK Jr publicly advocating for it, and the head of the FDA himself has said we need to be looking into these compounds. Lastly, FIVE  of these compounds now have Breakthrough Therapy designation which further accelerated approval and massively raises approval chances. Psychedelic Drugs with FDA Breakthrough Therapy Designation 1. CYB003 (Deuterated Psilocybin analog) - $CYBN (soon to be $HELP) A novel psilocybin-derived compound developed by Cybin for major depressive disorder (MDD). Received Breakthrough Therapy designation from the FDA. Designed to have a faster onset and shorter duration than classic psilocybin. Currently in advanced clinical trials (Phase 3) for MDD. � Wikipedia +1 2. MM120 (LSD-based compound) - $MMED A specially formulated LSD-derived drug being developed by MindMed for generalized anxiety disorder (GAD). Granted Breakthrough Therapy status based on promising clinical data. � Forbes 3. Psilocybin (COMP360; various formulations) - $CMPS Psilocybin itself has received Breakthrough Therapy designations through specific company programs (e.g., COMPASS Pathways’ COMP360 for treatment-resistant depression and Usona Institute’s psilocybin program for major depressive disorder). These designations date back to earlier in the decade and continue to support ongoing Phase 3 research. � Grass Roots NLP +1 4. 5-MeO-DMT (BPL-003) - $ATAI A novel intranasal formulation of 5-MeO-DMT developed by Atai Life Sciences and Beckley Psytech has recently been reported to receive FDA Breakthrough Therapy designation for treatment-resistant depression. This reflects growing interest in rapid-acting psychedelic treatments beyond psilocybin and LSD. �

Kachowxboxdad

Housing - Builders and Materials: ITB, QXO, DHI, LGIH Manufactured: SKY CVCO UMH ELS If portable mortgages or 40yr mortgages or lower rates hit: RKT Z COMP Look up road to housing 2025 and bessent/trump’s housing emergency declaration they floated. I think we’ll likely see a rate cut in a few days and then we need road to housing to pass the house. From there I think we’ll see the housing emergency declaration. I like manufactured housing because there is a lack of construction workers to build even if supply is incentivized. If road to housing hits it could work out very well. Unrelated but Cathie just spoke about housing potentially being a great 2026 trade https://youtu.be/S0FHyju1iRs?si=Vyg0zG-_WEyd-fka

Interesting_Bag2762

COMP overpaid for this shit merger in a down market and put a huge sign on their back asking regulators to f their shit up. No way you're gonna have 400k agents doing private listings dumbasses.

kanyedidnothingwr0ng

COMP if you want to get in on this rate cut thing with calls that are still cheap

HistoricalLychee9514

Its almost like everyone is obsessed with OPEN, Zillow, RKT and completely forgot about the sexy lexy COMP

Empty-Actuary6036

Isn’t Compass the perfect way to play the Fed cuts and get an easy 10x bagger? Their fundamentals are great and they are on the cutting edge with AI for realtors. Thoughts anyone? COMP. Plus, it would make a great meme name even thought the company legit

Lazy-Departure-5291

Mrvl calls will help me mod my new BMW M4 COMP

Lazy-Departure-5291

Workday puts is gonna get me that BMW M4 COMP today

divy-lover

I actually think they’ll do good. Look at COMP (compass). I used to work there and own a LOT of shares since it was $3. Slow and steady in my opinion

Extension_Arm6414

Get into a real company like COMP

bxlhustla

also it seems ATAI is selling CMPS major product, COMP360.

Extension_Arm6414

Balls deep in COMP calls for earnings

Extension_Arm6414

True. I got COMP calls as well

Proper-Breadfruit-34

Long: SOFI, NU, GOOG MID: HNST, COMP SHORT: LYFT, APLD

Professional_Buy_770

COMP AND GOPRO to the mooooooon

Professional_Buy_770

COMP AND GOPRO to the mooooooon

Mobile-Fisherman-791

COMP coin is the new big bull??

TheCitySnake

Buy your favourite home builder, mortgage company and real estate broker. You will notice they are low with rates st their highest in the cycle. I will be buying COMP calls in size.

Sad_Principle_2531

Nice, my goal is to make enough off markets to buy an M3 COMP, but even though I could sell my portfolio to buy one, i just can't.

foggy-moonlight

I totally see where you're coming from. Although COMP360 and natural mushrooms contain the same active compound, the key difference lies in purity, precision, and context of use. Simply put, COMP360 is a lab synthesized molecule developed for use in therapeutic settings, specifically for those who suffer from treatment resistant depression. It offers standardized dosing and medical oversight. In contrast, taking a bunch of dry mushrooms involves uncontrolled variables like like inconsistent potency, the presence of other alkaloids, and the absence of therapeutic structure.

WormFuckerNi66a

One key challenge to COMP360 is psilocybin is also on state level controlled substance acts. BUT a few states have had bills specifically mentioning COMP360. Even shithole states like Iowa have had bills mentioning it.

Every_University_749

Compass has targeted treatment-resistant depression, meaning patients have already sought treatment. Therefore, the DIY route argument isn't applicable. In my opinion, someone suffering from severe depression with suicidal ideation—like most of the TRD patients selected in Compass trials —should not attempt a heroic dose of psilocybin on their own. They should seek medical help. COMP360 has shown promising results as a treatment for treatment-resistant depression, PTSD, and anorexia nervosa.

SatoshiReport

Do you just make shit up for fun? Nasdaq https://indexes.nasdaqomx.com/docs/FS_COMP.pdf 5 year cumulative return 125% Scion https://stockcircle.com/portfolio/michael-burry/performance 5 year cumulative return 240%

Hussle_Crowe

WORKERS COMP. The ultimate yolo

Wild-Cow-5769

I caution you to be careful… There are significant historical trends that happen when the NASDAQ COMP gains 1% daily for 4 days in a row…

foggy-moonlight

They are working on a new medicine for treatment resistant depression. The drug they are working on is called Comp 360, and it is basically a proprietary, synthetic form of psilocybin that will need to be administered 3x a year. All data indicates that it will be way more effective at treating patients than what is currently available (intravenous ketamine, there is also a nasal spray). There is support for psychedelics in the current administration, including RFK Jr, Doug Collins who is the Veterans Affairs secretary, and also the head of the FDA Marty Makary. If their drug is effective and they get FDA approval for COMP 360, they will probably be acquired by an existing pharma company. Generally in biotech, positive phase 3 results are associated with a surge in the stock price so I'm optimistic. Currently the stock price is near all time lows. It's a steal. I am throwing a lot of my money at it.

Illustrious-Low4128

UNBANNED!!! DOES THAT MEAN I WON THE PAPER TRADING COMP???

PollenBasket

Still more interested in international equities. Just added GSIB, GREK, EWJV to my EU, CN and emerging market holdings. I have started to DCA a *little bit* of US like SONY, COMP, LTH, BRK-B, INOD, INTC, UBER.

oickles

Oh, I got you right here: https://www.forbes.com/sites/nathanvardi/2017/01/17/inside-the-obama-stock-markets-235-rise/ The 46th president of the United States is bringing his time at the White House to a close with the S&P 500 SPX up over 55% since he took office on Jan. 20, 2021. The Dow Jones Industrial Average DJIA advanced more than 39% over the same period, while the tech-heavy Nasdaq Composite COMP jumped nearly 46%, according to Dow Jones Market Data. Markets are struggling through a rocky stretch in the early months of President Donald Trump's second administration. The S&P 500 is down 7.1% since Trump's January 20th inauguration. The Index is 9.3% lower than its all-time high, achieved on February 19, 2025.5 days ago

CatsInJammers

Puts on Z? Or COMP looks like it’s sinking again

zzzzzz808

MINI DD: I going all in on Compass (COMP) tomorrow after hopefully a small pullback. I found out that they're basically like a combination of Uber and Zillow which caters to super rich and I was sold. What I mean by that is this: The way they are using their technology is potentially disruptive like Uber. They aren't just a marketplace like Zillow which makes money selling leads; they're a whole ass cloud-based real estate brokerage. Their work force pays them to use their platform which has a proprietary CRM system, automated marketing tools, analytics, and uses AI to help them determine the price, etc blah blah They also do a shit ton of acquisitions, and are gaining market share. For what dude said, they are retaining their agents. 25 percent of the short float was liquidated or covered today with almost no pullbacks. Still has a big short position, so if you go in keep that in mind, but I'm betting on this bitch gamma squeezing its way to 12 or 13. The way that it just melted up and added 1.5 billion dollars to its cap makes me think that 10 is the new base. Options are stupid fucking cheap for it. IV Rank: 11.45 Anyway I'm going all in tomorrow, don't be a fucking regard and follow me. Look it up and decide for yourself. https://preview.redd.it/tq8awsnke7ke1.png?width=1345&format=png&auto=webp&s=348541216c86fa30f6c09aa3d7f3f7a6396f22a2

DeeDee_Z

> I have no indicator what is "dividends" and what is "return of capital" Wanna know their "dirty little secret"? **Neither do they** ... until they close the books at the end of the year, and decide how much goes in each bucket. I own such a product, and the 1099-COMP that I get from Fidelity eventually itemizes where everything came from in each holding. For one of them, it turns out that **each** quarterly dividend was **exactly** 50% div and 50% NDD. Coincidence? I think not. (By the way, "depreciation" is also a Non-Div Distribution. Never been sure how that actually works, but it's in the paperwork...)

mrpuma2u

$COMP was it a pump and dump or anyone think it has legs for tomorrow?

jaffa_kree00

$COMP crypto been on a tear recently. Im up 70% and I'm adding. Its the lowest market cap on RH. All apes like me wanting the next coin are buyng this because i dont have a wallet but only can access crypto on RH

caprividog

Uh oh...RUT and DJI joining the COMP on the trend....SPY look out.

DeeDee_Z

> i just started investing this year ... what will be different when I file my taxes coming up? You'll get a tax form you've never seen before! One, two, maybe three of them; and major brokerages will package them into one bundle called a **1099-COMP**osite. This form will have several sections: 1099-INT, for any interest you earned (cash, money market funds), 1099-DIV, for any dividends your holdings paid out, and 1099-**B**, which lists all the trades and the gains/losses associated with each. If you use tax prep software -- and if you don't, it might be time to start -- All Ya Gotta Do Is: enter the data from those forms into your software when prompted. ---- Now, it can get more complicated than that, but that's where you start. If you received company stock, or exercised options, there are other things to deal with, but if you can copy data from one form to another, you can do this. AND, letting your software guide you through the process will also expose you to what actually goes into "doing taxes". Pay attention to that, and I guarantee that you'll be a smarter person four months from now than you are today!!

foggyharbour

CMPS. Previously I was holding calls for February 2025 as the expectation was phase 3 clinical trial results for their primary drug COMP 360 would be announced in December or January. However, due to enrolment delays they announced that phase 3 results won’t be released until Q2 2025. So unfortunately will have to wait a while longer. I’m rolling my calls over into May 2025 probably. The plus side is it’s dirt cheap right now, under $5. I’m doubling down and going to throw 10k at it, going to pick up some shares too. Feel free to see my post history for a DD post.

dysnoopian

$7.25 COMP calls

dysnoopian

Lost 4.5% on my portfolio today. Only my COMP holdings benefitted with positive earnings. MARA took a nice hit off me; glad I sold half my TESLA holdings on WED.

Drago_09

The question becomes will rivian prove to be a better investment then their own workers. If rivian delivers then ya, they would be. But if rivian fails, now they look double stupid. Although I think executives should get a 80% pay cut + wage and bonuses AND STOCK COMP freezes for 5 years. But they won’t do that. Some people in this subreddit are genuinely sick, what if you were one of the workers? Not only are you not getting a raise but ur actually getting a pay cut and guess what isn’t going down? Prices.

dsaysso

Thanks for sharing. It's this analysis and insight that's really great and helps lots of us. To see fundamentals can pay off. You saw a trend, bet with it, and it paid off. That said, I have been watching Compass. (COMP) just trying to see if there's a same pattern. If the pattern holds, it should break out for the next 2-4 days. (this is day 1) Then slowly consolidate down. Could go in for a quick uptick for 2-4 day then exit. Or, do a call followed by a put. https://preview.redd.it/vbsgnwpuqtqd1.png?width=1583&format=png&auto=webp&s=e228924eaef554238a87fa171918337d7f7cbedd

Ihateshortseller

Definitely COMP too. Just put your price target and date for COMP bro. I can't list every RE stocks that are crushed last 2 years 😂

spacecadet501st

Add COMP to that list too

CosmicSpiral

In technical terms? SPY and COMP:IND have been overbought since last Monday. Just look at their RSI profiles. Pullbacks are normal when buying has been hot. You run out of buyers, sellers take temporary control of price movement, and the market briefly retreats.

Ur_moms_box69

$COMP is the future

scotty_spivs

Compass $COMP, trading at ATH, but can continue to grow

Right_Specialist_720

Mental health treatment is indeed a crucial aspect of our society, and it's great to see companies like Compass Pathways working towards developing effective treatments. However, I have to agree with some of the commenters that the psychedelics-based approach raises some concerns. While COMP360 has shown promising results in phase II trials, we need to carefully consider the potential risks and side effects before investing. I'd love to hear more about Compass's plans for addressing these concerns and ensuring the safety of their treatment.

foggyharbour

COMP 360 is for *treatment resistant depression*. SSRIs do not work for TRD so it really isn’t a threat to Pfizer. If anything they would probably try to acquire them lmao. Currently, intravenous ketamine is basically the goto for TRD, I believe there is also a nasal spray. But the bottom line is COMP360 would not replace SSRIs. It would be an avenue for people to take if all other avenues have failed.

foggyharbour

It’s not the same at all. For one the psychedelic effect is very short lived in comparison. It’s highly controlled. And I am sorry to hear you lost 90%, a lot of people made the mistake of buying in when interest rates were low and the markets were inflated. MNMD imo was a scam from the start, but CMPS is the only reputable company in the sector and they will do amazing things with COMP360. This isn’t just my opinion.

foggyharbour

Got it. If shares I suggest looking into a company called Compass Pathways. I have been following them for years. I am building up my position with them because they have the results of their phase 3 clinical trials coming out in December for their psilocybin based drug for treatment resistant depression (COMP 360) and then in early 2025 I believe the phase 3 results for their drug for eating disorders are to be released. The results will almost certainly be very positive which will likely send the stock up. Biotech is generally risky and I would advise you to stay away from all companies in the mushroom/psychedelic medicine sector except for Compass Pathways. In particular don’t touch a scam company called Mind Medicine. Compass are maybe only one of 2 or 3 companies that will actually commercialize a psilocybin based treatment, and if they are successful, a larger pharmaceutical company could very well acquire them. Also if I’m right and the stock surges after positive phase 3 results take some profits, don’t hold everything indefinitely.

Spy300

>ULTA SEES FY COMP SALES -2% TO 0%, SAW +2% TO +3%, EST. +1.89 Becky's buy iPhones yall gonna put this together or what

moderationscarcity

why is COMP up 15% for the first time ever?

SkimmyMilk937

**Cryptocurrencies** * **BNB Coin (BNB)**: Native token of Binance, the largest cryptocurrency exchange. * **Uniswap (UNI)**: Governance token of the Uniswap decentralized exchange. * **Chainlink (LINK)**: Oracle network that provides smart contracts with access to real-world data. * **Polygon (MATIC)**: Layer-2 scaling solution for Ethereum. * **Aave (AAVE)**: Decentralized lending and borrowing protocol. **DeFi Projects** * **PancakeSwap (CAKE)**: Automated market maker and yield farming platform. * **SushiSwap (SUSHI)**: Another automated market maker and yield farming platform. * **Yearn Finance (YFI)**: Yield aggregation platform that optimizes returns. * **Compound (COMP)**: Decentralized money market that allows users to lend and borrow assets. * **MakerDAO (MKR)**: Decentralized stablecoin protocol that issues DAI. **Metaverse and Gaming** * **Axie Infinity (AXS)**: Blockchain-based game that allows players to breed, battle, and trade digital pets. * **Sandbox (SAND)**: Virtual world platform where users can create, monetize, and play games. * **Decentraland (MANA)**: Virtual world platform where users can own land, build structures, and interact with others. * **The Sandbox (SAND)**: Metaverse project with a focus on game creation and monetization. * **Gala (GALA)**: Decentralized gaming platform with its own native token. **Infrastructure and Protocols** * **Cosmos (ATOM)**: Blockchain interoperability protocol that allows different blockchains to communicate. * **Polkadot (DOT)**: Blockchain network that supports interoperable parachains. * **Ethereum Classic (ETC)**: Fork of the Ethereum blockchain that retains the original Proof-of-Work consensus mechanism. * **Helium (HNT)**: Decentralized wireless network that uses blockchain technology. * **Internet Computer (ICP)**: Blockchain that aims to provide a decentralized alternative to the internet.

IranianLawyer

Compass Inc. (COMP) Largest real estate brokerage in the country. They had their IPO back in 2021, and the stock has gone down like 90% since then, but it’s leveled off during the last couple of years and I feel like it eventually is going to rebound.

gitartruls01

COMP is not the same as [NDX](https://curvo.eu/backtest/en/market-index/nasdaq-100?currency=eur)

Trainer2002

Compass COMP buying buying buying

Joe_Early_MD

Uh oh bers: CPI days and Fed decision days both have a reputation for market volatility, but they rarely coincide. The CPI report and the Fed’s policy meeting have fallen on the same day only 13 times since 2008, according to Dow Jones Market Data. While the sample size is small, all three major stock indexes have tended to post gains on those days, with the S&P 500 SPX rising an average of 0.7%, the Dow Jones Industrial Average DJIA adding 0.9% and the Nasdaq Composite COMP advancing over 1%, according to Dow Jones Market Data

NoctRob

“This is a marketwide trading halt.” ROBINHOOD IS THE DEVIL!!! READING COMP IS FOR PAPERHAND CHADS!! Sigh…

Trainer2002

COMP - Compass real estate at an all low. loaded up on 5 dollar options long

cutiesarustimes2

Sbux CHINA COMP SALES -11%, EST. -1.62% 😮

Zero2Hero2MarginCall

BTC is the exact same risk profile now as every other S&P/COMP/DJI stock... institutions own it, intitutional algos control it

GOOG-Rally

There will be no compensation at COMP.

swez46

COMP

kestrel247

1Q NET REV. $9.43B, EST. $9.6B ( MISS ❌ ) 1Q COMP SALES +5%, EST. +6.39% ( MISS ❌ ) 1Q INTERNATIONAL COMP SALES +7%, EST. +11.6% ( MISS ❌ ) 1Q ADJ EPS 90C, EST. 93C ( MISS ❌ ) It's clear the boycott is working - I won't consider buying until the madness is over... What's newscord?

--Right--Tackle--

"A team of quantitative strategists at J.P. Morgan see shades of the dotcom bubble in the stock-market rally that has carried the S&P 500 to six record closing highs since the beginning of 2024. According to the team of analysts led by Khuram Chaudhry, the persistently rising concentration in the U.S. stock market has become an important risk that investors should be aware of in 2024. Although there are several important differences between the dotcom-bubble era and today, Chaudhry and his team insist that the two periods are more similar than one might initially expect. "When viewed in a historical context, parallels to the 'Dotcom Bubble' era are often dismissed due to the 'irrational exuberance' that characterized this period. In this note, we demonstrate that there are a plethora of similarities between these two periods," Chaudhry and his team wrote in a note viewed by MarketWatch on Tuesday. The analysis comes at a time when the lopsided nature of stock-market returns over the past year has heavily favored shares of the largest U.S.-traded companies, a group that has earned the nickname "the Magnificent Seven." These stocks drove the bulk of the S&P 500's 24.2% gain last year, according to FactSet, and have continued to outperform since the beginning of 2024. As a result, the concentration in the U.S. market is nearing its highest level since 2000. To wit, the top-five stocks now account for 21.7% of the MSCI USA Index XX:984000 as of the end of 2023, according to J.P. Morgan's numbers, while the share of the top 10, which includes all of the Magnificent Seven, has risen to 29.3%. For the top five, this level is within 0.7 percentage points of the post-1994 peak of 22.4% from March 2000. The current top 10 are moderately further below their historical peak share of 33.2%, which occurred in June 2000. Still, by both measures, concentration is the highest it has been since the dotcom days. The MSCI USA Index has 609 constituent stocks and is intended to measure the performance of large and midcap U.S.-traded stocks, according to an MSCI fact sheet on the index. In its analysis, the J.P. Morgan team focused on several factors. For example, they determined that the number of sectors represented among the top 10 most valuable companies is actually less diverse in 2024 than it was during the peak of the dotcom bubble. Back then, there were six sectors represented among the top 10 stocks, compared with just four today. What's more, they found that during both periods, information-technology companies represented the biggest share of the group's total market capitalization. Valuations, meanwhile, mark another important difference between the dotcom era and the present day. During the dotcom era, the J.P. Morgan strategists found that forward price-to-earnings for the top 10 largest companies in the U.S. market peaked at 41.2x expected earnings. Currently, the top 10 are valued at 26.8x. But the J.P. Morgan team highlighted an important caveat. They took the reciprocal of forward price-to-earnings, a metric known as the forward earnings yield, and measured the spread between the top 10 stocks in the MSCI USA Index and the rest of the index. What they found is that as recently as October, the top 10 stocks in the index commanded the highest premium to earnings relative to the rest of the index on record - although since then, the premium has shrank considerably. Meanwhile, the J.P. Morgan strategists found that the share of overall EPS growth contributed by the 10 largest stocks was actually larger during the dotcom days - helping to rebut the conventional wisdom around the period as one where stocks had become completely disconnected from fundamentals. "While we would be hesitant to refer to the current levels of the Top 10 as a bubble, it would certainly appear that the Top 10 in the Dotcom era was backed by superior earnings developments," the J.P. Morgan team said. Finally, the strategists measured the difference in price returns between the top 10 stocks and the rest of the U.S. index. They found that, generally speaking, periods of strong outperformance are typically followed by bouts of mean reversion. This would suggest that Big Tech is overdue for a period where it lags behind the broader market, like it did in 2022. Cautious about the chances of a Big Tech-led selloff, the J.P. Morgan team warned clients that they "do expect equity market drawdowns to materialize, which may well be driven by weakness in the Top 10." Most of the Magnificent Seven stocks were trading lower on Tuesday - with Nvidia Corp. (NVDA) and Tesla Inc. (TSLA) shares flat, Microsoft Corp. (MSFT) and Alphabet Inc. (GOOGL) shares off by less than 1%, and Apple Inc. (AAPL) and Amazon.com Inc. (AMZN) shares moving sharply lower. Meta Platforms Inc. (META) shares were the only member of the group trading higher on the day. Weakness among the Big Tech names contributed to a 0.7% drop in the Nasdaq Composite COMP to 15,525. Meanwhile, the S&P 500 SPX was off by 0.1% at 4,924, still within striking distance of its most recent record closing high."

Less-Orchid-2527

This entire tech bubble rally is 100% synthetic and fake. Forget all about any rate cuts. The secret to stocks’ success so far in 2023? An unexpected $1 trillion liquidity boost by central banks. They printed 1 trillion $ last 100 days only to pump the market to ATH at end of 2023. Gains for global equities have left many on Wall Street perplexed as stocks — especially high-risk growth names with little or no profits — have rebounded from last year’s punishing selloff, resisting both the pull of more attractive bond yields, and the threat of higher interest rates. But some Wall Street analysts say they’ve found an explanation that has little to do with inflation and the state of the global economy. The upshot is this: The Federal Reserve, European Central Bank and Bank of England have advertised that they’re trying to drain the ocean of banking-system liquidity, (but on a global scale, liquidity has actually increased in recent months). That’s due in part to factors that are outside the control of policy makers. A trillion-dollar boost to asset prices In a research note shared with clients last month, Matt King, a global markets strategist at Citigroup Inc., detailed how the world’s largest central banks had recently injected $1 trillion into the global financial system. The bulk of this increase, according to King’s analysis, came from the People’s Bank of China, which has bucked the trend of global monetary tightening and instead opted to directly inject liquidity into its banking system, accounting for the largest share of the $1 trillion figure. “Even as the central banks have told us they’re going to be tightening, it turns out that on at a global level, they’ve just added $1 trillion worth of liquidity over the past three months,” King said. In his report, King said he was inspired to take a closer look at central-bank balance sheets after concluding that changes in the fundamentals — meaning the outlook for the economic growth and inflation — failed to explain moves across global markets, including a rebound in global equity prices. When he finally mapped moves in global equities against the shifting tides of global central bank liquidity, he found that they were a near-perfect fit. The chart below tracks the performance of the MSCI World Index 990100, +0.27% against the ebbs and flows of banking-system liquidity. The index has risen 12% since the end of September, according to FactSet data. Around the same time, global central bank liquidity stopped ebbing, and started expanding once more. For more than a year now, the Federal Reserve has been trumpeting its plans to “tighten” liquidity in the U.S. financial system by raising interest rates and reducing its bond holdings by opting not to reinvest the proceeds from maturing bonds. And while the size of the Fed’s bond holdings has shrunk since last spring by about $500 billion, according to data from the St. Louis Fed, another important component of its balance sheet, U.S. banking system reserves, appears to have flat-lined. According to the latest weekly update released by the Fed, reserve balances at Federal Reserve banks stood at $3.01 trillion as of Feb 22. That’s a modest increase from $2.9 trillion at the end of September. “The Fed is supposedly rolling off the balance sheet, but bank reserves are not falling,” Howell said. This could also be helping to buttress equity prices as the amount of money available for U.S. banks to push into the financial system has expanded, instead of contracting, he said. Stocks coming off the boil To be sure, U.S. stocks have come off the boil in recent weeks following a torrid rally that resulted in the Nasdaq Composite COMP, -0.32% rising more than 10% in January for its best start to a year in two decades, according to FactSet data. That stocks are no longer climbing could be a sign that the liquidity tide is ebbing once again. Whether it will once again come to the market’s rescue remains to be seen. But it’s certainly possible that ultimately, equity valuations could suffer as a result. According to Howell and his team, it’s possible the Fed may need to hike interest rates more aggressively to compensate for its unwillingness to further cull banking system reserves. After resisting their pull for a few weeks, U.S. stocks appear to be feeling the effects of higher bond yields. The Nasdaq Composite, S&P 500 SPX, -0.10% and Dow Jones Industrial Average DJIA, 0.12% all lost ground in February. They were putting in a mixed performance on Thursday as the yield on the 10-year Treasury note topped 4%. Bond yields move inversely to prices.

DSBandicoot

Yeah I mean I get that its iffy, been playing ETH, AVAX, and COMP. So today I just upped those positions.

dysnoopian

Tesla, Crypto and oddly COMP with the interest rates dropped momentum.

dingoshiba

Real estate sector. I like COMP

DonCorletony

I work in mortgages. Personally i think RKT is better than COMP because Rocket Mortgage is the single biggest mortgage company in the world with a billion dollars cash on hand and an excellent reputation. However i also have 25% of my mortgage YOLO money in COMP because Compass is also a good company and theyre on the rise. Mortgages are already picking up substantially just on the mere announcement of upcoming rate cuts. Interest rates have dropped a half a percent. Once the rate cuts come and refis start rolling in i think its gonna be a multibagger. Up im 80% on RKT and 30% on COMP, so im happy

ParticularElk8457

COMP looks promising

DonCorletony

If you want to capitalize on rates going down, pick up RKT or COMP

purplecatfishbettie

psylocybin could be big... [https://finance.yahoo.com/quote/CMPS?p=CMPS](https://finance.yahoo.com/quote/CMPS?p=CMPS) " COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom. "

ee08b021

What's going on with COMP? All the other ZIRP stocks are mooning like crazy but not this.

DonCorletony

Id suggest just doing your own DD and leaving it at that People said i was dumb and downvoted me for saying mortgage companies and BoA were good plays because of how beaten down they are Now BoA is doing great and im up 60% on RKT and 40% on COMP

cutiesarustimes2

COSTCO 1Q US COMP SALES EX-GAS, FX +2.6%, EST. +3.48% *COSTCO 1Q TOTAL CO. COMP SALES INCL GAS, FX +3.8%, EST. +4.3% $COST And it's up

DonCorletony

Just wanted to come back and say im up 60% on RKT and 40% on COMP

LisleSwanson

$COMP They're down a shit ton since their IPO. It's at $2.39 right now. Feb 2024 $2.5p are $0.50 and $1p are $0.10 I'm in for the $10p gamble

t1mmen

Fair concerns, though I’d expect when/if COMP360 works as expected, they’re safe, and the floodgates will be open. With current burn rate (roughly $100m/yr) and the cash on hand + latest dilution, we’re well into 26/27. FDA Fast track designation should help keep the timeline as short as possible. MAPS getting (presumably) FDA approval for MDMA will very likely raise further public awareness and investor interest in the sector. I’d be hesitant to compare this field to recreational cannabis. While I am a big believer in “do whatever you want with your own body, so long as it doesn’t hurt anyone else”, I’m not betting on the rec plays of the sector. FDA approval and insurance coverage is where it’s at, financially. Public awareness seems, in my echo chamber, to be at an all time high.

Extension-Sky-9187

You will likely underperform if you invest into the big companies only going forward in my opinion small caps have a lot of value it will drive much of the returns but good job on outperforming, one year however does not mean anything! You also need an investing theme not just random stocks, I feel like you are just picking completely randomly selected stock! I would focus on ROCE HIGH FCF PER SHARE GROWTH AND SUSTAINABLE COMP ADV COMPANIES. One book i would recommend is terry smith investing for growth

_hiddenscout

$SBUX 3Q NET REV. $9.2B, EST. $9.28B 3Q ADJ EPS $1.00, EST. 95C 3Q COMP SALES +10%, EST. +11.1% 3Q NORTH AMERICA COMP SALES +7%, EST. +8.25% 3Q INTERNATIONAL COMP SALES +24%, EST. +24.1% Looks to be down 1.73 in the AHs

AP9384629344432

> he Nasdaq Composite (COMP.IND) closed 2.05% lower at 14,063.31 points, notching its worst day since early March Even though it's just a 2% sell-off, I think it feels as bad as it does to some because it's the worst we've seen in 4 months! The year has gone by real quick. Surprising to me, I'd have thought we had a random 2-3% sell-off at some point in May or June...

deathlyharry

COMP and BCH have been going fuckin crazy

bfishinc

Might get buried in the 300+ comments but COMP. They’ve done a high quality job of integrating various steps of the home purchasing process into one platform under one brokerage. I used to work at a mortgage company and going through the hoops of different people at different companies just for one question on a title policy was always a major slowdown. Compass is solving this. They’ve held up better than the rest of the market in the downturn, they’re still expanding, and management seems confident in the next 3 quarters being FCF positive. I’ll also throw VFC into the lot. I don’t own it yet but I might soon. Great recognizable brands (in spite of Supreme write down). Revenue down a touch with profit down a lot but expected to recover. Decent amount of insider buying as the price has gone lower. Dividend cut has freed up cash. Moodys still holds them as investment grade. I want to do more investigation into their debt picture but I may nibble at some shares.

_hiddenscout

$ULTA 1Q EPS $6.88, EST. $6.80 1Q NET SALES $2.6B, EST. $2.62B 1Q COMP SALES +9.3%, EST. +8.85% STILL SEES FY EPS $24.70 TO $25.40, EST. $25.41 SEES FY NET SALES $11.0B TO $11.1B, SAW $10.95B TO $11.05B STILL SEES FY COMP SALES +4% TO +5%, EST. +5.18% Down around 9% in AHs

Jellybingus11

$COMP still a good buy right noq despite the 90% run up the past couple weeks

Jellybingus11

$COMP finally getting a nice rebound

Jellybingus11

$COMP is the real estate stock to get right now. Gonna rebound harder than the others, up almost 100% since begjnning of last week

Jellybingus11

$COMP is the play next week. Last earnings beat in Nov had a huge run the week following.

Jellybingus11

Hoping for $COMP to keep popping

Jellybingus11

$COMP

Jellybingus11

$COMP up 75% in last 5 trading days. Said yesterday it would pump after earnings and it gained 35% today. Still plenty of more upside.

Itscooo

RDFN should be 🚀- see COMP results?

Jellybingus11

$COMP pumping tomorrow